Retrospective evaluation of the predictive value of tumour burden at baseline [68 Ga]Ga-DOTA-TOC or -TATE PET/CT and tumour dosimetry in GEP-NET patients treated with PRRT

放射性核素治疗 医学 核医学 神经内分泌肿瘤 生长抑素受体 回顾性队列研究 多塔 生长抑素 内科学 肿瘤科 放射科 化学 有机化学 螯合作用
作者
Anni Gålne,Anna Sundlöv,Olof Enqvist,Katarina Sjögreen Gleisner,Erik Larsson,Elin Trägårdh
出处
期刊: 卷期号:8 (1): 24-24 被引量:3
标识
DOI:10.1186/s41824-024-00210-y
摘要

Abstract Purpose There is a lack of validated imaging biomarkers for prediction of response to peptide receptor radionuclide therapy (PRRT). The primary objective was to evaluate if tumour burden at baseline PET/CT could predict treatment outcomes to PRRT with [177Lu]Lu-DOTA-TATE. Secondary objectives were to evaluate if there was a correlation between tumour burden and mean tumour absorbed dose (AD) during first cycle, and if mean tumour AD or the relative change of tumour burden at first follow-up PET/CT could predict progression free survival (PFS) or overall survival (OS). Methods Patients with gastroenteropancreatic neuroendocrine tumour (GEP-NET) treated with [177Lu]Lu-DOTA-TATE PRRT were retrospectively included. Tumour burden was quantified from [68 Ga]Ga-DOTA-TOC/TATE PET/CT-images at baseline and first follow-up and expressed as; whole-body somatostatin receptor expressing tumour volume (SRETVwb), total lesion somatostatin receptor expression (TLSREwb), largest tumour lesion diameter and highest SUVmax. The relative change of tumour burden was evaluated in three categories. Mean tumour AD was estimated from the first cycle of PRRT. PFS was defined as time from start of PRRT to radiological or clinical progression. OS was evaluated as time to death. Kaplan Meier survival curves and log-rank test were used to compare PFS and OS between different groups. Results Thirty-one patients had a baseline PET/CT < 6 months before treatment and 25 had a follow-up examination. Median tumour burden was 132 ml (IQR 61–302) at baseline and 71 ml (IQR 36–278) at follow-up. Twenty-two patients had disease progression (median time to progression 17.2 months) and 9 patients had no disease progression (median follow-up 28.7 months). SRETVwb dichotomized by the median at baseline was not associated with longer PFS (p = 0.861) or OS (p = 0.937). Neither TLSREwb, largest tumour lesion or SUVmax showed significant predictive value. There was a moderately strong correlation, however, between SUVmax and mean tumour AD r = 0.705, p < 0.001, but no significant correlation between SRETVwb nor TLSREwb and mean tumour AD. An increase of SRETVwb, TLSREwb or largest tumour lesion at first follow-up PET/CT was significantly correlated with shorter PFS/OS. Conclusion Tumour burden at baseline showed no predictive value of PFS/OS after PRRT in this small retrospective study. An increase of tumour burden was predictive of worse outcome.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
tao完成签到 ,获得积分10
刚刚
MSN完成签到,获得积分10
1秒前
英俊的铭的应助被奥丁蒂法采纳,获得10
1秒前
1秒前
yhhhhhha发布了新的文献求助10
2秒前
2秒前
momo完成签到,获得积分10
3秒前
Anita发布了新的文献求助10
3秒前
3秒前
科研汪发布了新的文献求助10
3秒前
4秒前
乐乐的应助被渟柠采纳,获得10
4秒前
光亮天蓉发布了新的文献求助10
5秒前
xxxxxxxxxx发布了新的文献求助10
5秒前
miumiu521发布了新的文献求助10
6秒前
guoting完成签到,获得积分10
6秒前
专注数据线给专注数据线的求助进行了留言
6秒前
syvshc的应助被freecare采纳,获得10
8秒前
小蘑菇的应助被Sun采纳,获得10
8秒前
9秒前
lyr完成签到,获得积分10
10秒前
希望天下0贩的0的应助被Qin采纳,获得10
10秒前
温暖伟祺完成签到,获得积分10
10秒前
东风的应助被liriyii采纳,获得10
11秒前
11秒前
12秒前
14秒前
执着的导师的应助被cw采纳,获得10
14秒前
mashiyi完成签到,获得积分10
14秒前
15秒前
Fay完成签到,获得积分10
15秒前
15秒前
周一发布了新的文献求助10
15秒前
sunday完成签到,获得积分10
15秒前
NexusExplorer的应助被王一硕采纳,获得10
16秒前
今后的应助被王一硕采纳,获得10
16秒前
李健的应助被枫丶采纳,获得10
16秒前
16秒前
呀呀呀完成签到 ,获得积分10
17秒前
渟柠发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193425
求助须知:如何正确求助?哪些是违规求助? 9579620
关于积分的说明 21866505
捐赠科研通 7793025
什么是DOI,文献DOI怎么找? 3437297
关于科研通互助平台的介绍 2560718
邀请新用户注册赠送积分活动 2484128